Pathology of Experimental Aerosol Zaire Ebolavirus Infection in Rhesus Macaques

Veterinary Pathology

Volumn 50, Issue 3, 2013, Pages 514-529

  Twenhafel, N A ^a   Mattix, M E ^a   Johnson, J C ^a   Robinson, C G ^a   Pratt, W D ^a   Cashman, K A ^a   Wahl Jensen, V ^b   Terry, C ^a   Olinger, G G ^a   Hensley, L E ^a   Honko, A N ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

aerosol; animal model; ebolavirus; filovirus; macaque; rhesus; Zaire; Zaire ebolavirus

Indexed keywords

AEROSOL; ANIMAL; ANIMAL MODEL; ARTICLE; BIOLOGICAL WARFARE AGENT; BLOOD; BODY TEMPERATURE; DEMOCRATIC REPUBLIC CONGO; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FEMALE; FILOVIRUS; HUMAN; LIVER; LUNG; LYMPH NODE; LYMPHOID TISSUE; MACACA; MALE; PATHOGENICITY; PATHOLOGY; RESPIRATORY SYSTEM; RHESUS; RHESUS MONKEY; SPLEEN; VIREMIA; VIROLOGY; VIRUS REPLICATION; ZAIRE EBOLAVIRUS;

AEROSOL; ANIMAL MODEL; EBOLAVIRUS; FILOVIRUS; MACAQUE; RHESUS; ZAIRE; ZAIRE EBOLAVIRUS;

AEROSOLS; ANIMALS; BIOLOGICAL WARFARE AGENTS; BODY TEMPERATURE; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; LIVER; LUNG; LYMPH NODES; LYMPHOID TISSUE; MACACA MULATTA; MALE; MODELS, ANIMAL; RESPIRATORY SYSTEM; SPLEEN; VIREMIA; VIRUS REPLICATION;

ANIMALIA; EBOLA VIRUS; MACACA; MACACA MULATTA; MARBURGVIRUS; ZAIRE EBOLAVIRUS;

EID: 84876982494     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985812469636     Document Type: Article

References (85)

1. Alibek K,Handelman SBiohazard. New York, NY: Random House; 1999:.
2. Alves DA,Glynn AR,Steele KE, et al.Aerosol exposure to the Angola strain of Marburg virus causes lethal viral hemorrhagic fever in cynomolgus macaques.Vet Pathol. 2010;47 (5): 831-851.
3. Anderson AO,Anderson ND.Studies on the structure and permeability of the microvasculature of normal rat lymph nodes.Am J Pathol. 1975;80 (3): 387-418.
4. Anderson ND,Anderson AO,Wyllie RG.Specialized structure and metabolic activities of high endothelial venules in rat lymphatic tissues.Immunology. 1976;31:455-473.
5. Baize S,Leroy EM,Georges-Courbot MC, et al.Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.Nat Med. 1999;5 (4): 423-426.
6. Baron RC,McCormick JB,Zubeir OA.Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread.Bull World Health Organ. 1983;61:997-1003.
7. Baskerville A,Fisher-Hoch SP,Neild GH, et al.Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection.J Pathol. 1985;147:199-209.
8. Bausch DG,Towner JS,Dowell SF, et al.Assessment of the risk of Ebola virus transmission from bodily fluids and fomites.J Infect Dis. 2007;196 (suppl 2): 142-147.
9. Bente D,Gren J,Strong JE, et al.Disease modeling for Ebola and Marburg viruses.Dis Model Mech. 2009;2:12-17.
10. Bilyk N,Holt PG.Inhibition of the immunosuppressive activity of resident pulmonary alveolar macrophages by granulocyte/macrophage colony-stimulating factor.J Exp Med. 1993;177:1773-1777.
11. Borio L,Inglesby T,Peters CJ, et al.Hemorrhagic fever viruses as biological weapons: medical and public health management.JAMA. 2002;287:2391-2405.
12. Bosio CM,Aman JF,Grogan C, et al.Ebola and Marburg viruses replicate in monocytes-derived dendritic cells without inducing the production of cytokines and full maturation.J Infect Dis. 2003;188:1630-1638.
13. Bray M,Geisbert TW.Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever.Int J Biochem Cell Biol. 2005;37 (8): 1560-1566.
14. Bray M,Davis K,Geisbert T, et al.A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.J Infect Dis. 1999;179:248-258.
15. Bruce J,Brysiewicz P.Ebola fever: the African emergency.Int J Trauma Nurs. 2002;8:36-41.
16. Bwaka MA,Bonnet MJ,Calain P, et al.Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients.J Infect Dis. 1999;179:S1-S7.
17. Carette JE,Raaben M,Wong AC, et al.Ebola virus entry requires the cholesterol transporter Neimann-Pick C1.Nature. 2011;477 (7364): 340-343.
18. Update: outbreak of Ebola viral hemorrhagic fever-Zaire.MMWR Morb Mortal Wkly Rep. 1995;44:468-469.
19. Update: outbreak of Ebola viral hemorrhagic fever-Zaire.MMWR Morb Mortal Wkly Rep. 1995;44:381-382.
20. Update: outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001.MMWR Morb Mortal Wkly Rep. 2001;50:73-77.
21. Update: outbreak of Ebola viral hemorrhagic fever-Zaire, 1995.MMWR Morb Mortal Wkly Rep. 1995;44 (20): 399.
22. Chen JP,Cosgriff TM.Hemorrhagic fever virus-induced changes in hemostasis and vascular biology.Blood Coagul Fibrinolysis. 2000;11 (5): 461-483.
23. Connolly BM,Steele KE,Davis KJ, et al.Pathogenesis of experimental Ebola virus infection in guinea pigs.J Infect Dis. 1999;179:203-217.
24. Cote M,Misasi J,Ren T, et al.Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection.Nature. 2011;477 (7364): 344-348.
25. Dabisch PA,Kline J,Lewis C, et al.Characterization of a head-only aerosol exposure system for nonhuman primates.Inhal Toxicol. 2010;22:224-233.
26. Dalgard DW,Hardy RJ,Pearson SL, et al.Combined simian hemorrhagic fever and Ebola virus infection in cynomolgus monkeys.Lab Anim Sci. 1992;42:152-157.
27. Davis KJ,Anderson AO,Geisbert TW, et al.Pathology of experimental Ebola virus infection in African green monkeys: involvement of fibroblastic reticular cells.Arch Pathol Lab Med. 1997;131 (8): 805-819.
28. Dembeck ZF,Martin JW,Christopher GW, et alMedical Aspects of Biological Warfare. Dembeck ZF, ed. Washington, DC: Borden Institute; 2007:1-10.
29. Bull World Health Organ. 1978:271-293.
30. Ellis DS,Simpson IH,Francis DP, et al.Ultrastructure of Ebola virus particles in human liver.J Clin Pathol. 1978;31:201-208.
31. Elmore S.Apoptosis: a review of programmed cell death.Tox Pathol. 2007;35:495-517.
32. Eitzen EM,Takafuji ETMedical Aspects of Chemical and Biological Warfare. Sidell FRTakafuji ETFranz DR, ed. Washington, DC: Borden Institute; 1997:415-424.
33. Feldmann H,Jones SM,Daddario-diCaprio KM, et al.Effective post-exposure treatment of Ebola infection.PLoS Pathol. 2007;3:e2.
34. Fisher-Hoch SP,Brammer TL,Trappier SG, et al.Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain.J Infect Dis. 1992;166:753-763.
35. New drug and biological drug products: evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible.Fed Regist. 2002;67:37988-37998.
36. Gear HS.Clinical aspects of African viral hemorrhagic fevers.Rev Infect Dis. 1989;11 (suppl 4): 5777-5782.
37. Geisbert TW,Hensley LE,Gibb TR, et al.Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses.Lab Invest. 2000;80:171-186.
38. Geisbert TW,Hensley LE,Larsen T, et al.Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.Am J Pathol. 2003;163 (6): 2347-2370.
39. Geisbert TW,Jahrling PB.Differentiation of filoviruses by electron microscopy.Virus Res. 1995;39:129-150.
40. Geisbert TW,Young HA,Jahrling PB, et al.Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells.Am J Pathol. 2003;163:2371-2382.
41. Gretz JE,Anderson AO,Shaw S.Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex.Immunol Rev. 1997;156:11-24.
42. Gupta M,Mahanty S,Ahmed R, et al.Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC induced IFN-alpha in vitro.Virology. 2001;284:20-25.
43. Hanna KE.Extraordinary measures for countermeasures to terrorism: FDA's "animal rule.".Hastings Cent Rep. 2002;32:9.
44. Hartings JM,Roy CJ.The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates.J Pharmacol Toxicol Methods. 2004;49:39-55.
45. Hauer J,Henderson DA,Johnson RT, et al.Hemorrhagic fever viruses as biological weapons: medical and public health management.JAMA. 2002;287:2391-2405.
46. Hensley LE,Geisbert TW.The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates.Thromb Haemost. 2005;94:254-261.
47. Hensley LE,Stevens EL,Yan SB, et al.Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.J Infect Dis. 2007;196 ((suppl 2)): 390-399.
48. Holt PG,Oliver J,Bilyk N, et al.Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages.J Exp Med. 1993;177:397-407.
49. Illera VA,Perandones CE,Stunz LL, et al.Apoptosis in splenic B lymphocytes.J Immunol. 1993;151:2965-2973.
50. Isaacson M,Sureau P,Courteille G, et alEbola Virus Haemorrhagic Fever. Pattyn SR, ed. New York, NY: Elsevier/North-Holland Biomedical Press; 1976:15-20.
51. Jaax NK,Davis KJ,Geisbert TJ, et al.Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure.Arch Pathol Lab Med. 1996;120:140-155.
52. Jahrling PB,Geisbert JV,Swearengen JR, et al.Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates.J Infect Dis. 2007;196 (suppl 2): 400-403.
53. Johnson E,Jaax N,White J, et al.Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus.Int J Exp Pathol. 1995;76:227-236.
54. Kirby AC,Coles MC,Kay PM.Alveolar macrophages transport pathogens to lung draining lymph nodes.J Immunol. 2009;183:1983-1989.
55. Kortepeter M,Bray BD.Basic clinical and laboratory features of filoviral hemorrhagic fever.J Infect Dis. 2011;204 (suppl 3): 810-816.
56. Kuhn JH,Becker S,Ebihara H, et al.Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations.Arch Virol. 2010;155:2083-2103.
57. Lambrecht BN,Prins JB,Hoogsteden HC.Lung dendritic cells and host immunity to infection.Eur Respir J. 2001;18:692-704.
58. Mantovani A,Bussolino F,Dejana E.Cytokine regulation of endothelial cell function.EMBO J. 1992;6:2591-2599.
59. Mohamadzadeh M,Chen L,Olinger GG, et al.Filoviruses and the balance of innate, adaptive, and inflammatory responses.Viral Immunol. 2006;19 (4): 602-612.
60. Moncada S,Palmer RMJ,Higgs EA.Relationship between proacyclin and nitric oxide in the thrombotic process.Thromb Res Suppl. 1990;11:3-13.
61. Murphy FAEbola Virus Haemorrhagic Fever. SR Pattyn, ed. New York, NY: Elsevier/North-Holland Biomedical Press; 1978:43-60.
62. Pratt WD,Wang D,Nichols DK, et al.Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.Clin Vaccine Immunol. 2010;17:572-581.
63. Reed DS,Hensley LE,Geisbert JB, et al.Depletion of peripheral blood T lymphocytes and NK cells during the course of Ebola hemorrhagic fever in cynomolgus macaques.Viral Immunol. 2004;17 (3): 390-400.
64. Roy CJ,Reed DS,Hutt AJ.Aerobiology and inhalation exposure to biological select agents.Vet Pathol. 2010;47 (5): 799-789.
65. Ryabchikova EI,Price BBEbola and Marburg Viruses: A View of Infection Using Electron Microscopy. Columbus, OH: Battelle Press; 2004:.
66. Sanchez A,Kukwiya M,Bausch D, et al.Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels.J Virol. 2004;78:370-377.
67. Shurtleff AC,Warren TK,Bavari S.Nonhuman primates as models for the discovery and development of ebolavirus therapeutics.Expert Opin Drug Discov. 2011;6 (3): 233-250.
68. Snoy PJ.Establishing efficacy of human products using animals: the US Food and Drug Administration's "animal rule.".Vet Pathol. 2010;47 (5): 774-778.
69. Steele KE.Guest editorial: special focus on the pathology of biological select agents and toxins in animals and research challenges in biological defense.Vet Pathol. 2010;47 (5): 772-773.
70. Steele KE,Anderson AO,Mohamadzadeh M.Fibroblastic reticular cell infection by hemorrhagic fever viruses.Immunotherapy. 2009;1 (2): 187-197.
71. Steele KE,Anderson AO,Mohamadzadeh M.Fibroblastic reticular cells and their role in viral hemorrhagic fevers.Expert Rev Anti Infect Ther. 2009;7 (4): 423-435.
72. Steele KE,Crise B,Kuehne A, et al.Ebola virus glycoprotein demonstrates differential cellular localization in infected cell types of nonhuman primates and guinea pigs.Arch Pathol Lab Med. 2001;125 (5): 625-630.
73. Trombley AR,Wachter L,Garrison J, et al.Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses.Am J Trop Med Hyg. 2010;82 (5): 954-960.
74. Twenhafel NA.Pathology of inhalational anthrax animal models.Vet Pathol. 2010;47 (5): 819-830.
75. Twenhafel NA,Alves DA,Purcell BK.Pathology of inhalational Francisella tularensis spp. tularensis SCHU S4 infection in African green monkeys (Chlorocebus aethiops).Vet Pathol. 2009;46:698-706.
76. Guidance for industry: animal models-essential elements to address efficacy under the animal rule.Fed Regist. 2009;74:3610-3611.
77. US Department of Health and Human Services, Food and Drug Administration, Title 21 Code of Federal Regulations Part 58.
78. US Department of Health and Human Services, Food and Drug Administration, Title 21 Code of Federal Regulations, Subpart I, Section 314.600.
79. Waquier N,Becquart P,Padilla C, et al.Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.PLoS Negl Trop Dis. 2010;4 (10): e837.
80. Warfield KL,Swenson DL,Olinger GG, et al.Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidatemorpholino oligomers.PLoS Pathog. 2006;2:e1.
81. Wenk EJ,Orlic D,Reith EJ, et al.The ultrastructure of mouse lymph node venules and the passage of lymphocytes across their walls.J Ultrastruct Res. 1974;47:214-241.
82. Ebola hemorrhagic fever in Zaire, 1976.Bull World Health Organ. 1978;56 (2): 271-293.
83. Zaki SR,Goldsmith CS.Pathologic features of filovirus infections in humans.Curr Top Microbiol Immunol. 1999;235:97-116.
84. Zaki SR,Shieh WJ,Greer PW, et al.A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever: Commission de Lutte contre les Epidemies a Kikwit.J Infect Dis. 1999;179:36-47.
85. Zhao L,Burt DA.The diffuse stellate cell system.J Mol Hist. 2007;38:53-64.